BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol. 2009;28:24-27. [PMID: 19529898 DOI: 10.1007/s12664-009-0005-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg. 2011;45:301-321. [PMID: 21954696 DOI: 10.1016/j.yasu.2011.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
2 Talar-Wojnarowska R, Gasiorowska A, Olakowski M, Lekstan A, Lampe P, Malecka-Panas E. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis. Pancreatology 2010;10:689-94. [PMID: 21242708 DOI: 10.1159/000320693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
3 Rammohan A, Cherukuri SD, Palaniappan R, Perumal SK, Sathyanesan J, Govindan M. Preoperative Platelet–Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis. World J Surg 2015;39:2323-8. [DOI: 10.1007/s00268-015-3087-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 98] [Article Influence: 12.2] [Reference Citation Analysis]
5 Hinton J, Callan R, Bodine C, Glasgow W, Brower S, Jiang S, Li J. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas. Expert Review of Molecular Diagnostics 2014;13:431-43. [DOI: 10.1586/erm.13.38] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
6 Saraswat M, Joenväärä S, Seppänen H, Mustonen H, Haglund C, Renkonen R. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis. Cancer Med 2017;6:1738-51. [PMID: 28573829 DOI: 10.1002/cam4.1107] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
7 Perumal S, Palaniappan R, Pillai SA, Velayutham V, Sathyanesan J. Predictors of malignancy in chronic calcific pancreatitis with head mass. World J Gastrointest Surg 2013;5:97-103. [PMID: 23717745 DOI: 10.4240/wjgs.v5.i4.97] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
8 Sivaraman A, Muthukrishnan A, Boopathy Senguttvan N, Anil Suchak S, Kannan U. Predictors of malignancy in pancreatic head mass: a prospective study. Pan Afr Med J 2011;9:30. [PMID: 22145063 DOI: 10.4314/pamj.v9i1.71206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Brauner E, Lachter J, Ben-Ishay O, Vlodavsky E, Kluger Y. Autoimmune pancreatitis misdiagnosed as a tumor of the head of the pancreas. World J Gastrointest Surg. 2012;4:185-189. [PMID: 22905288 DOI: 10.4240/wjgs.v4.i7.185] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Farina A. Proximal fluid proteomics for the discovery of digestive cancer biomarkers. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2014;1844:988-1002. [DOI: 10.1016/j.bbapap.2013.10.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
11 Jazieh KA, Foote MB, Diaz LA Jr. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma. Semin Radiat Oncol 2014;24:67-76. [PMID: 24635863 DOI: 10.1016/j.semradonc.2013.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
12 Dutta AK, Chacko A. Head mass in chronic pancreatitis: Inflammatory or malignant. World J Gastrointest Endosc 2015;7:258-64. [PMID: 25789097 DOI: 10.4253/wjge.v7.i3.258] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
13 Parikh DA, Durbin-Johnson B, Urayama S. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population. J Gastrointest Cancer 2014;45:74-9. [PMID: 24272911 DOI: 10.1007/s12029-013-9563-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sabetkish N, Sabetkish S, Mohseni MJ, Kajbafzadeh AM. Prevention of Renal Scarring in Acute Pyelonephritis by Probiotic Therapy: an Experimental Study. Probiotics Antimicrob Proteins 2019;11:158-64. [PMID: 29204797 DOI: 10.1007/s12602-017-9363-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cao X, Wang X, Xu X, Lu Y, Zhao B, Zhang X, Chen Q. Pancreatoduodenectomy for Periampullary Tumors Presenting with Acute Pancreatitis. Gastroenterol Res Pract 2020;2020:7246895. [PMID: 32190043 DOI: 10.1155/2020/7246895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pandiaraja J, Viswanathan S, Antomy TB, Thirumuruganand S, Kumaresan DS. The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas. J Clin Diagn Res 2016;10:PC06-9. [PMID: 27134925 DOI: 10.7860/JCDR/2016/17106.7398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Xia J, Zhang H, Guan Q, Wang S, Li Y, Xie J, Li M, Huang H, Yan H, Chen T. Qualitative diagnostic signature for pancreatic ductal adenocarcinoma based on the within-sample relative expression orderings. J Gastroenterol Hepatol 2021;36:1714-20. [PMID: 33150986 DOI: 10.1111/jgh.15326] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Garcea G, Metcalfe MS, Berry DP, Robertson GS, Lloyd DM, Dennison AR. Is Intraoperative Confirmation of Malignancy During Pancreaticoduodenectomy Mandatory? J Gastrointest Surg 2012;16:370-5. [DOI: 10.1007/s11605-011-1728-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
19 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Reference Citation Analysis]
20 Igbinigie E, Guo F, Jiang SW, Kelley C, Li J. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. Clin Chim Acta. 2019;488:226-234. [PMID: 30452897 DOI: 10.1016/j.cca.2018.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
21 Miglani RK, Bhateja N, Bhat RS, Kumar KV. Diagnostic Role of Platelet Lymphocyte Ratio(PLR) in Pancreatic Head Masses. Indian J Surg 2013;75:4-9. [PMID: 24426375 DOI: 10.1007/s12262-012-0443-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
22 Kaur S, Chakraborty S, Baine MJ, Mallya K, Smith LM, Sasson A, Brand R, Guha S, Jain M, Wittel U, Singh SK, Batra SK. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One. 2013;8:e55171. [PMID: 23383312 DOI: 10.1371/journal.pone.0055171] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
23 Botsis T, Anagnostou VK, Hartvigsen G, Hripcsak G, Weng C. Modeling prognostic factors in resectable pancreatic adenocarcinomas. Cancer Inform 2010;7:281-91. [PMID: 20508721 DOI: 10.4137/cin.s3835] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Dhar P, Kalghatgi S, Saraf V. Pancreatic cancer in chronic pancreatitis. Indian J Surg Oncol 2015;6:57-62. [PMID: 25937765 DOI: 10.1007/s13193-014-0373-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
25 Vijayakumar A, Vijayakumar A. Imaging of focal autoimmune pancreatitis and differentiating it from pancreatic cancer. ISRN Radiol 2013;2013:569489. [PMID: 24967284 DOI: 10.5402/2013/569489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
26 van Heerde MJ, Biermann K, Zondervan PE, Kazemier G, van Eijck CH, Pek C, Kuipers EJ, van Buuren HR. Prevalence of autoimmune pancreatitis and other benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Dig Dis Sci. 2012;57:2458-2465. [PMID: 22588243 DOI: 10.1007/s10620-012-2191-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
27 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
28 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
29 Camara SN, Ramdany S, Zhao G, Gou SM, Xiong JX, Yang ZY, Yin T, Yang M, Balde OT, Barry AB. Etiology, pathology, management and prognosis of chronic pancreatitis in Chinese population: A retrospective study. J Huazhong Univ Sci Technolog Med Sci. 2015;35:384-389. [PMID: 26072078 DOI: 10.1007/s11596-015-1442-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 208] [Reference Citation Analysis]
31 van Heerde MJ, Buijs J, Hansen BE, de Waart M, van Eijck CHJ, Kazemier G, Pek CJ, Poley JW, Bruno MJ, Kuipers EJ, van Buuren HR. Serum Level of Ca 19-9 Increases Ability of IgG4 Test to Distinguish Patients with Autoimmune Pancreatitis from Those with Pancreatic Carcinoma. Dig Dis Sci. [DOI: 10.1007/s10620-013-3004-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
32 Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15-22. [PMID: 22729569 DOI: 10.1002/jso.23192] [Cited by in Crossref: 137] [Cited by in F6Publishing: 134] [Article Influence: 15.2] [Reference Citation Analysis]